Cardiff Oncology, Inc. (NASDAQ:CRDF) Stock Position Raised by Bank of New York Mellon Corp

Bank of New York Mellon Corp lifted its position in shares of Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 68.7% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 288,615 shares of the company's stock after acquiring an additional 117,514 shares during the period. Bank of New York Mellon Corp owned 0.56% of Cardiff Oncology worth $1,253,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. HB Wealth Management LLC bought a new position in Cardiff Oncology in the 4th quarter worth about $105,000. Barclays PLC grew its holdings in Cardiff Oncology by 291.9% in the 3rd quarter. Barclays PLC now owns 53,089 shares of the company's stock worth $141,000 after buying an additional 39,542 shares in the last quarter. Rhumbline Advisers increased its position in Cardiff Oncology by 24.0% in the 4th quarter. Rhumbline Advisers now owns 53,172 shares of the company's stock valued at $231,000 after acquiring an additional 10,290 shares during the period. XTX Topco Ltd raised its stake in Cardiff Oncology by 44.3% during the 3rd quarter. XTX Topco Ltd now owns 120,384 shares of the company's stock valued at $321,000 after acquiring an additional 36,947 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Cardiff Oncology by 11.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 121,293 shares of the company's stock worth $324,000 after acquiring an additional 12,503 shares during the period. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Trading Down 2.8 %

CRDF stock traded down $0.10 during trading hours on Thursday, hitting $3.44. 1,485,616 shares of the stock traded hands, compared to its average volume of 1,072,635. The stock has a 50-day simple moving average of $4.00 and a 200 day simple moving average of $3.43. Cardiff Oncology, Inc. has a one year low of $2.01 and a one year high of $6.38. The company has a market cap of $228.84 million, a P/E ratio of -3.66 and a beta of 1.73.

Remove Ads

Analyst Upgrades and Downgrades

CRDF has been the topic of a number of recent analyst reports. HC Wainwright lifted their price objective on shares of Cardiff Oncology from $13.00 to $17.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Piper Sandler boosted their price target on shares of Cardiff Oncology from $7.00 to $10.00 and gave the stock an "overweight" rating in a research report on Friday, December 13th.

About Cardiff Oncology

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.